Skip to main content
. Author manuscript; available in PMC: 2020 Feb 9.
Published in final edited form as: Clin Cancer Res. 2017 Dec 7;24(5):1038–1047. doi: 10.1158/1078-0432.CCR-17-2289

Figure 2. Survival comparisons according to targeted therapy.

Figure 2.

Survival curves for subjects with any of sEGFR, ERBB2, BRAF p.V600E (veBRAF), ALKr, ROS1r, RETr, or METamp alterations who received targeted therapy (Ttx), versus those with similar alterations who did not receive targeted therapy (No Ttx), versus those with no mutations in any of these genes.